JAK2V617F allele burden ≥50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy

被引：47

作者：

Barosi, G. ^{[1
]}

Klersy, C. ^{[2
]}

Villani, L. ^{[1
]}

Bonetti, E. ^{[1
]}

Catarsi, P. ^{[1
]}

Poletto, V. ^{[1
]}

Campanelli, R. ^{[1
]}

Impera, S. ^{[3
]}

Latagliata, R. ^{[4
]}

Viarengo, G. ^{[5
]}

Carolei, A. ^{[1
]}

Massa, M. ^{[1
]}

Musso, M. ^{[6
]}

Crescimanno, A. ^{[6
]}

Gale, R. P. ^{[7
]}

Rosti, V. ^{[1
]}

机构：

[1] IRCCS Policlin S Matteo Fdn, Ctr Study Myelofibrosis, Biotechnol Res Area, Pavia, Italy

[2] IRCCS Policlin S Matteo Fdn, Biometry & Clin Epidemiol, Pavia, Italy

[3] Presidio Osped Garibaldi Nesima, Hematol, Catania, Italy

[4] Univ Rome, Dept Cellular Biotechnol & Hematol, La Sapienza, Italy

[5] IRCCS Policlin S Matteo Fdn, Immunohematol & Transfus Serv, Pavia, Italy

[6] UO Oncol & Trapianto Midollo, Dipartimento Oncol La Maddalena, Palermo, Italy

[7] Imperial Coll London, Haematol Res Ctr, Dept Med, Div Expt Med, London, England

来源：

LEUKEMIA | 2016年 / 30卷 / 08期

关键词：

INTERNATIONAL-WORKING-GROUP; MYELOPROLIFERATIVE NEOPLASMS RESEARCH; TREATMENT IWG-MRT; MYELOID METAPLASIA; CRITERIA;

D O I：

10.1038/leu.2016.45

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1772 / 1775

页数：6

共 12 条

[1] Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia [J].

Barosi, G ;

Viarengo, G ;

Pecci, A ;

Rosti, V ;

Piaggio, G ;

Marchetti, M ;

Frassoni, F .

BLOOD, 2001, 98 (12) :3249-3255

[2] Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper [J].

Barosi, Giovanni ;

Vannucchi, Alessandro M. ;

De Stefano, Valerio ;

Pane, Fabrizio ;

Passamonti, Francesco ;

Rambaldi, Alessandro ;

Saglio, Giuseppe ;

Barbui, Tiziano ;

Tura, Sante .

LEUKEMIA RESEARCH, 2014, 38 (02) :155-160

[3] Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis [J].

Guglielmelli, Paola ;

Rotunno, Giada ;

Bogani, Costanza ;

Mannarelli, Carmela ;

Giunti, Laura ;

Provenzano, Aldesia ;

Giglio, Sabrina ;

Squires, Matthew ;

Stalbovskaya, Viktoriya ;

Gopalakrishna, Prashanth ;

Vannucchi, Alessandro M. .

BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (06) :938-940

[4] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis [J].

Harrison, Claire ;

Kiladjian, Jean-Jacques ;

Al-Ali, Haifa Kathrin ;

Gisslinger, Heinz ;

Waltzman, Roger ;

Stalbovskaya, Viktoriya ;

McQuitty, Mari ;

Hunter, Deborah S. ;

Levy, Richard ;

Knoops, Laurent ;

Cervantes, Francisco ;

Vannucchi, Alessandro M. ;

Barbui, Tiziano ;

Barosi, Giovanni .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (09) :787-798

[5] Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status [J].

Medinger, Michael ;

Skoda, Radek ;

Gratwohl, Alois ;

Theocharides, Alexandre ;

Buser, Andreas ;

Heim, Dominik ;

Dirnhofer, Stephan ;

Tichelli, Andre ;

Tzankov, Alexandar .

BRITISH JOURNAL OF HAEMATOLOGY, 2009, 146 (02) :150-157

[6] A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) [J].

Passamonti, Francesco ;

Cervantes, Francisco ;

Vannucchi, Alessandro Maria ;

Morra, Enrica ;

Rumi, Elisa ;

Pereira, Arturo ;

Guglielmelli, Paola ;

Pungolino, Ester ;

Caramella, Marianna ;

Maffioli, Margherita ;

Pascutto, Cristiana ;

Lazzarino, Mario ;

Cazzola, Mario ;

Tefferi, Ayalew .

BLOOD, 2010, 115 (09) :1703-1708

[7] Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib [J].

Patel, Keyur P. ;

Newberry, Kate J. ;

Luthra, Rajyalakshmi ;

Jabbour, Elias ;

Pierce, Sherry ;

Cortes, Jorge ;

Singh, Rajesh ;

Mehrotra, Meenakshi ;

Routbort, Mark J. ;

Luthra, Madan ;

Manshouri, Taghi ;

Santos, Fabio P. ;

Kantarjian, Hagop ;

Verstovsek, Srdan .

BLOOD, 2015, 126 (06) :790-797

[8] JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders [J].

Plo, Isabelle ;

Nakatake, Mayuka ;

Malivert, Laurent ;

de Villartay, Jean-Pierre ;

Giraudier, Stephane ;

Villeval, Jean-Luc ;

Wiesmuller, Lisa ;

Vainchenker, William .

BLOOD, 2008, 112 (04) :1402-1412

[9] Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis [J].

Rampal, Raajit ;

Al-Shahrour, Fatima ;

Abdel-Wahab, Omar ;

Patel, Jay P. ;

Brunel, Jean-Philippe ;

Mermel, Craig H. ;

Bass, Adam J. ;

Pretz, Jennifer ;

Ahn, Jihae ;

Hricik, Todd ;

Kilpivaara, Outi ;

Wadleigh, Martha ;

Busque, Lambert ;

Gilliland, D. Gary ;

Golub, Todd R. ;

Ebert, Benjamin L. ;

Levine, Ross L. .

BLOOD, 2014, 123 (22) :E123-E133

[10] International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT) [J].

Tefferi, Ayalew ;

Barosi, Giovanni ;

Mesa, Ruben A. ;

Cervantes, Francisco ;

Deeg, H. Joachim ;

Reilly, John T. ;

Verstovsek, Srdan ;

Dupriez, Brigitte ;

Silver, Richard T. ;

Odenike, Olatoyosi ;

Cortes, Jorge ;

Wadleigh, Martha ;

Solberg, Lawrence A., Jr. ;

Camoriano, John K. ;

Gisslinger, Heinz ;

Noel, Pierre ;

Thiele, Juergen ;

Vardiman, James W. ;

Hoffman, Ronald ;

Cross, Nicholas C. P. ;

Gilliland, D. Gary ;

Kantarjian, Hagop .

BLOOD, 2006, 108 (05) :1497-1503

← 1 2 →